Chiao‐En Wu

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

Ping‐Chih Hsu, Suey-Haur Lee, Li‐Chung Chiu et al. · Targeted Oncology · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang et al. · Cancers · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon <scp><i>EGFR</i></scp> mutations: Real‐world data from Taiwan

John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang et al. · Thoracic Cancer · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +14

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Chiao‐En Wu, Ching‐Fu Chang, Chen‐Yang Huang et al. · BMC Cancer · 2021 · 20 citations · Full text

Medicine, Oncology, Pharmacology +9

Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platforms.

John Wen‐Cheng Chang, Nien-Chih Wei, Hung-Ju Su et al. · PubMed · 2012 · 18 citations

Life Sciences, Molecular Biology, Oncology +17